(secondQuint)Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen.

 The optimal treatment for PCV is still under debate.

 Little knowledge is known about the treatment effect of "1+pro re nata(PRN)" treatment regimen for PCV.

 The aim of this study is to compare the outcomes of different treatment methods including PDT, IVR and combination therapy under the "1+PRN" treatment regimen for PCV.

 The study is the first prospective randomized controlled trial about different treatment methods on PCV under "1+PRN" treatment regimen.

 The null hypothesis of the study is that combination therapy may be the optimal treatment method for PCV.

 The primary outcome measures is the Best-corrected visual acuity (BCVA) of the participants at 1 year after treatment.

 Besides, the slit-lamp examination, tonometry, funduscopy, and OCT, FFA, ICGA examinations will also be compared between different groups to find the optimal treatment for PCV.

.

 Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen@highlight

The aim of this study is to compare the outcomes of different treatment methods including photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy under the "1+PRN" treatment regimen for polypoidal choroidal vasculopathy (PCV) and find the optimal treatment for PCV.

